Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality® (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults.
Share this post
Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email